-+ 0.00%
-+ 0.00%
-+ 0.00%

Pharvaris' RAPIDe-3 Phase 3 Trial Of Deucrictibant For The On-demand Treatment Of Hereditary Angioedema Attacks Met The Primary Endpoint Of Median Time To Onset Of Symptom Relief, Achieved In 1.28 Hours, Significantly Faster Than Placebo

Benzinga·12/03/2025 11:56:24
Listen to the news
  • Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)
  • All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours)
  • Well-tolerated safety profile of deucrictibant confirmed
  • Efficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with normal C1 inhibitor) and varying attack severities and locations